Intrinsic Therapeutics

Intrinsic Therapeutics is a commercial-stage medical device company that has developed and markets the Barricaid annular closure device. The device is clinically proven to reduce reherniation and subsequent reoperation rates in lumbar discectomy patients with large annular defects, addressing a significant unmet need in spine surgery. With over two decades of development and a strong body of published clinical evidence, including Level 1 RCT data, the company is focused on driving surgeon adoption and patient access. Its business model centers on the sale of the implantable device to hospitals and surgical centers.

Bone-anchored annular closure device (Barricaid) - a flexible polymer barrier anchored to vertebral bone to occlude the annular defect post-discectomy, preventing reherniation.

Operates in the specialized spine device market. Barricaid is a first-mover in the bone-anchored annular closure segment. Competes indirectly with other discectomy augmentation techniques, biological implants, and the standard of care (discectomy alone). Its primary competitive advantage is its robust, long-term clinical data.